Sponsor: MUSC
Sponsor Study ID: 103629
Study Title: Phase II Trial of Sparing the Urethra, Pudendal Artery and Rectum During Stereotactic Ablative Body Radiotherapy (SUPR-SABR) for Favorable and Intermediate Risk Prostate Cancer
CTO #: 103629
NCT Number: NCT05668351
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Prostate
Study Objectives: To evaluate the 12-month patient reported GU and GI toxicity of SUPR- SABR.1. To further evaluate the toxicity profile of SUPR-SABR based on: 24-month Expanded Prostate Cancer Index Composite (EPIC) urinary and bowel domain scores (patient reported), Incidence of CTCAE grade 3 or higher safety events (physician reported), 1-month GU toxicity